ENGN enGene Therapeutics
enGene Therapeutics earnings company data as of 5:13 AM ET 9/16
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 10 Sep | EPS | -0.43 | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by ENGN's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $10K bought by 1 insider
- None no sales outside a trading plan
- None no planned (10b5-1) sales
-
William Grossman Interim Chief Medical OfficerBuy$10K 5,102 shares at $1.97 New stakeTraded Sep 22 Filed Sep 24
SEC filings
Recent issuer filings from EDGAR, 25 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 8.01,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 7.01,9.01 | Filing Doc | |
| 8-K | 5.02,7.01,9.01 | Filing Doc | |
| 8-K/A | 2.05,5.02 | Filing Doc | |
| 8-K | 2.02,2.05,5.02,7.01,8.01,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 5.07,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| DEF 14A | Filing Doc | ||
| 8-K | 5.02,7.01,8.01,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 5.03,7.01,9.01 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 1.01,1.02,9.01 | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.